Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)

Background In the phase III TAGS trial, trifluridine/tipiracil showed survival benefit versus placebo in patients with metastatic gastric/gastroesophageal junction cancer and ≥ 2 prior chemotherapies. This post hoc exploratory analysis assessed the impact of prior therapy type on outcomes. Methods B...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cancer research and clinical oncology 2023-09, Vol.149 (11), p.9361-9374
Hauptverfasser:	Shitara, Kohei, George, Ben, Taieb, Julien, Sundar, Raghav, Fakih, Marwan G., Makris, Lukas, Benhadji, Karim A., Ghidini, Michele
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Antiviral drugs Cancer Cancer Research Clinical trials Colorectal Neoplasms - pathology Drug Combinations Esophagogastric Junction - pathology Gastric cancer Hematology Humans Internal Medicine Irinotecan Irinotecan - therapeutic use Medicine Medicine & Public Health Metastases Metastasis Oncology Paclitaxel Paclitaxel - therapeutic use Patients Placebos Pyrrolidines Safety Stomach Neoplasms - drug therapy Survival therapeutics Trifluridine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!